Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 142,620
  • Shares Outstanding, K 25,651
  • Annual Sales, $ 430 K
  • Annual Income, $ -26,830 K
  • 60-Month Beta 2.99
  • Price/Sales 305.43
  • Price/Cash Flow N/A
  • Price/Book 7.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.26
  • Number of Estimates 1
  • High Estimate -0.26
  • Low Estimate -0.26
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -360.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.10 +9.02%
on 11/14/19
6.99 -20.46%
on 10/16/19
-0.08 (-1.42%)
since 10/15/19
3-Month
4.86 +14.40%
on 10/10/19
8.64 -35.65%
on 09/20/19
-2.36 (-29.80%)
since 08/15/19
52-Week
4.20 +32.38%
on 11/16/18
13.70 -59.42%
on 02/13/19
+0.91 (+19.57%)
since 11/15/18

Most Recent Stories

More News
CorMedix (CRMD) Reports Q3 Loss, Misses Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CRMD : 5.56 (+8.59%)
CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 5.56 (+8.59%)
CorMedix Inc. to Report Third Quarter 2019 Financial Results and Provide a Corporate Update on November 14

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 5.56 (+8.59%)
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRMD : 5.56 (+8.59%)
CorMedix Inc. Announces a Change to its Senior Leadership

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 5.56 (+8.59%)
CorMedix Completes Successful CMC Interaction with the FDA

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 5.56 (+8.59%)
CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 5.56 (+8.59%)
CorMedix Inc. Announces Exercises of Outstanding Warrants

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 5.56 (+8.59%)
CorMedix Inc. to Present at the H.C. Wainwright 21st Annual Global Investment Conference

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 5.56 (+8.59%)
CorMedix Inc. Announces Exchange Agreement With Its Largest Investor

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 5.56 (+8.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRMD with:

Business Summary

CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular...

See More

Key Turning Points

2nd Resistance Point 5.99
1st Resistance Point 5.77
Last Price 5.56
1st Support Level 5.27
2nd Support Level 4.98

See More

52-Week High 13.70
Fibonacci 61.8% 10.07
Fibonacci 50% 8.95
Fibonacci 38.2% 7.83
Last Price 5.56
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar